Efficacy of Sitafloxacin-Based Rescue Therapy for Helicobacter pylori after Failures of First- and Second-Line Therapies | Zendy

Juntaro Matsuzaki | Zendy; Hidekazu Suzuki | Zendy; Toshihiro Nishizawa | Zendy; Kenro Hirata | Zendy; Hitoshi Tsugawa | Zendy; Yoshimasa Saito | Zendy; Sawako Okada | Zendy; Seiichiro Fukuhara | Zendy; Toshifumi Hibi∥ | Zendy

Open Access

Efficacy of Sitafloxacin-Based Rescue Therapy for Helicobacter pylori after Failures of First- and Second-Line Therapies

Author(s) -

Juntaro Matsuzaki,

Hidekazu Suzuki,

Toshihiro Nishizawa,

Kenro Hirata,

Hitoshi Tsugawa,

Yoshimasa Saito,

Sawako Okada,

Seiichiro Fukuhara,

Toshifumi Hibi∥

Publication year - 2011

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.05941-11

Subject(s) - helicobacter pylori , metronidazole , clarithromycin , medicine , helicobacter , mutation , rescue therapy , first line , antibiotics , gastroenterology , microbiology and biotechnology , biology , genetics , gene

Sitafloxacin-based triple therapy achieved 83.6% (per-protocol) and 78.2% (intention-to-treat) success in eradicating Helicobacter pylori among 78 Japanese patients after clarithromycin-based first-line and metronidazole-based second-line triple therapies failed. Eradication succeeded in 32 out of 43 patients, even with gyrA mutation-positive Helicobacter pylori (per protocol). The position of the gyrA mutation (N87 or D91) was determined to be a better marker than MIC levels for predicting outcomes of sitafloxacin-based treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research